PT 141

Clinical Study on PT-141 and references  

Based on the information from various sources, including clinical trials and research studies, PT-141, also known as Bremelanotide, has been extensively studied for its potential effects on sexual desire and sexual dysfunction. Here are some key insights from the available sources:  

CLINICAL STUDIES AND SAFETY:  

• PT-141 has been clinically proven to increase sexual desire in both animal and human studies, with a favorable safety profile. It is indicated to treat low sexual desire in women in the United States and has been extensively tested as a potential treatment for erectile dysfunction    
  
  .  
• A 52-week study monitored PT-141 use in premenopausal women with hypoactive sexual desire disorder and found that the treatment remained effective for the duration of the study. However, the long-term effects of PT-141 have not yet been widely studied, and caution is advised regarding its safety and efficacy over extended periods, especially for individuals with other health conditions    
   
  .  

POTENTIAL THERAPEUTIC APPLICATIONS:  

• PT-141 has shown promising results in enhancing women’s libido, as demonstrated through scientific studies. It was originally developed from the Melanotan II hormone, which is known to generate skin-darkening pigments. However, during clinical trials of Melanotan II, it was observed that the compound also stimulated sexual arousal, leading to the development of PT-141     
  .  

SAFETY AND EFFICACY IN MEN:  

• PT-141 is only available by prescription as Vyleesi, and there are no approved prescriptions for men hoping to use PT-141 for erectile dysfunction. However, it has been evaluated in healthy male subjects and in patients with erectile dysfunction, demonstrating statistically significant erectile responses and a favorable safety profile    
  
  .  

In conclusion, the available evidence suggests that PT-141 has shown potential in clinical studies for increasing sexual desire and addressing sexual dysfunction, particularly in women. However, caution should be exercised in interpreting the findings, and further research, including well-controlled clinical trials, is needed to fully understand its efficacy, safety, and potential therapeutic applications in diverse patient populations.  

Please note:  

• This product is sold for scientific research purposes only.  
• This product is a lyophilized (freeze-dried) powder packaged in a sealed, sterile vial.  
• The quantity listed on the label refers to the total amount of product in each vial.  
• Additional lab supplies will be required for conducting research such as bacteriostatic water for reconstitution, syringes, to draw from the vials, and alcohol prep pads for sanitizing vial stoppers.